Aishu Sukumar is an associate director in the health and life sciences team at Gates Ventures, where she oversees the Alzheimer’s disease (AD) biomarker and diagnostics portfolio. In collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF), Sukumar manages the Diagnostics Accelerator, a venture philanthropy fund focused on advancing peripheral and digital biomarker development to bring scalable, minimally invasive, and low-cost diagnostics for AD to market. She also leads and supports workstreams related to biomarkers, diagnostics, and sustainability within multiple Institute for Healthcare Improvement initiatives, including the European Platform for Neurodegeneration, AD-RIDDLE, and SYNTHIA.

Sukumar earned her MBA and MPH from the University of California, Berkeley, Haas School of Business and School of Public Health. She also has a background in life sciences strategy consulting, specializing in commercialization strategy, revenue forecasting, competitive landscape assessment, drug pricing, and market access for pharmaceutical and biotech companies. Sukumar had five years of biomedical research training across the Wyss Institute at Harvard Medical School, University of Cambridge, and Carnegie Mellon University.